Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 6:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Prostate Cancer Diagnosis Clear all
Completed Phase 1 Interventional

Phase 1 of EC1169 In Patients With Recurrent MCRPC

NCT02202447
View directory record Official record
Conditions
Prostate Cancer
Interventions
EC1169, EC0652
Drug · Other
Lead sponsor
Endocyte
Industry
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
Scottsdale, Arizona • New Haven, Connecticut • New Orleans, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Sep 27, 2026, 6:45 PM EDT
Completed Not applicable Interventional

Pain and Fatigue Management in Patients With Breast Cancer, Prostate Cancer, Colon Cancer, or Lung Cancer

NCT00900835
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Fatigue, Lung Cancer, Pain, Prostate Cancer
Interventions
educational intervention, questionnaire administration, study of socioeconomic and demographic variables, assessment of therapy complications, fatigue assessment and management, quality-of-life assessment, standard follow-up care
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2011 · Synced Sep 27, 2026, 6:45 PM EDT
Recruiting Phase 1 Interventional

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

NCT04890613
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
CX-5461
Drug
Lead sponsor
Senhwa Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
6
States / cities
Santa Monica, California • Tampa, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 27, 2026, 6:45 PM EDT
Completed Phase 1 Interventional

Novel PET/CT Agents and MRS/MRI in Prostate CA and High Risk Prostate Cancer: An Inter-SPORE Collaboration

NCT00987376
View directory record Official record
Conditions
Prostate Cancer
Interventions
Diagnostic Imaging: C11 choline PET; C11 acetate PET; and MRI Spectroscopy
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 12, 2016 · Synced Sep 27, 2026, 6:45 PM EDT
Recruiting Phase 3 Interventional

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

NCT07213674
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Xaluritamig, Abiraterone acetate, Docetaxel, Cabazitaxel
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Male only
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
45
States / cities
Goodyear, Arizona • Tucson, Arizona • Duarte, California + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 27, 2026, 6:45 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Internet-Based Education for Prostate Cancer Screening

NCT00623090
View directory record Official record
Conditions
Prostate Cancer
Interventions
educational internet site on prostate cancer screening, Educational print booklet, Usual care
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
45 Years to 70 Years · Male only
Enrollment
1,893 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 12, 2012 · Synced Sep 27, 2026, 6:45 PM EDT
Completed No phase listed Observational Results available

A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer

NCT01306890
View directory record Official record
Conditions
Advanced Prostate Cancer, Prostatic Neoplasms
Interventions
sipuleucel-T
Biological
Lead sponsor
Dendreon
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,976 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
333
States / cities
Bessemer, Alabama • Birmingham, Alabama • Huntsville, Alabama + 245 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2019 · Synced Sep 27, 2026, 6:45 PM EDT
Completed Phase 2 Interventional Results available

Use of Low Dose Ketoconazole in Prostate Cancer That Does Not Respond to Hormone Therapy and Prior Chemotherapy

NCT00895310
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ketoconazole, Hydrocortisone
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Sep 27, 2026, 6:45 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer

NCT04898634
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
JNJ-78278343
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
New York, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 27, 2026, 6:45 PM EDT
Completed Phase 3 Interventional Results available

Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer

NCT00519285
View directory record Official record
Conditions
Prostatic Neoplasms, Neoplasm Metastasis
Interventions
Aflibercept, Placebo (for aflibercept), Docetaxel, Prednisone or Prednisolone
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 21, 2016 · Synced Sep 27, 2026, 6:45 PM EDT
Terminated Phase 1 Interventional

Pilot Study of Mobilization and Treatment of Disseminated Tumor Cells in Men With Metastatic Prostate Cancer

NCT02478125
View directory record Official record
Conditions
Prostate Cancer
Interventions
Burixafor Hydrobromide, Docetaxel, G-CSF
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 17, 2019 · Synced Sep 27, 2026, 6:45 PM EDT
Completed Phase 1Phase 2 Interventional

A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)

NCT05708950
View directory record Official record
Conditions
Cancer, Solid Tumor, Melanoma, Carcinoma, Sarcoma, Lung Cancer, Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Uterine Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Thyroid Cancer, Ovarian Cancer, Kidney Cancer, Head and Neck Cancer
Interventions
KVA12123 - Dose Escalation, KVA12123 Plus Pembrolizumab - Dose Escalation, KVA12123 - Dose Expansion, KVA12123 Plus Pembrolizumab - Dose Expansion
Drug
Lead sponsor
Kineta Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
Santa Monica, California • Denver, Colorado • Sarasota, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 27, 2026, 6:45 PM EDT
Withdrawn Phase 1 Interventional

A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer

NCT02396368
View directory record Official record
Conditions
Prostate Cancer, Bone-only Metastatic Castration-Resistant Prostate Cancer (CRPC)
Interventions
Tasquinimod, Radium 223
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2015 · Synced Sep 27, 2026, 6:45 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs

NCT07336446
View directory record Official record
Conditions
Prostate Cancer
Interventions
AZD9750, AZD5305
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
8
States / cities
Duarte, California • San Francisco, California • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 27, 2026, 6:45 PM EDT
Terminated Phase 1 Interventional Results available

PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors

NCT03685591
View directory record Official record
Conditions
Breast Neoplasms, Prostate Neoplasms, Neoplasms, Squamous Cell, Melanoma, Mesothelioma, Pancreatic Neoplasms, Colorectal Neoplasms, Carcinoma, Renal Cell, Liver Neoplasms
Interventions
PF-06952229, Enzalutamide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
15
States / cities
Scottsdale, Arizona • Santa Monica, California • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 27, 2026, 6:45 PM EDT
Withdrawn Phase 2 Interventional

Ciprofloxacin Compared to Placebo in Diagnosing Prostate Cancer in Patients Undergoing Prostate Biopsy

NCT02252978
View directory record Official record
Conditions
Prostate Cancer
Interventions
ciprofloxacin, placebo, quality-of-life assessment, laboratory biomarker analysis
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Salisbury, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Sep 27, 2026, 6:45 PM EDT
Completed Phase 1 Interventional

Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer.

NCT01692262
View directory record Official record
Conditions
Metastatic Castrate-Resistant Prostate Cancer (mCRPC),, Efficacy,, Safety and Tolerability,, Pharmacokinetics,, Pharmacodynamics,, Tumour Response.
Interventions
Intermittent dosing of AZD5363
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
5
States / cities
Sarasota, Florida • Boston, Massachusetts • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2014 · Synced Sep 27, 2026, 6:45 PM EDT
Completed Not applicable Interventional Results available

DMH-Based Plan Evaluation and Inverse Optimization in Radiotherapy

NCT02663817
View directory record Official record
Conditions
Head and Neck Cancer, Lung Cancer, Prostate Cancer
Interventions
CT Scan
Device
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 27, 2026, 6:45 PM EDT
Completed Not applicable Interventional

Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET)

NCT02080650
View directory record Official record
Conditions
Prostate Cancer, Renal Cell Carcinoma, Bladder Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Non-small Cell Lung Cancer, Advanced MET Amplified Solid Tumor
Interventions
Mesenchymal-marker based ferrofluid (c-MET), Epithelial cell adhesion molecule (EpCAM) ferrofluid
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Sep 27, 2026, 6:45 PM EDT
Completed No phase listed Observational

Prostate Cancer Survey

NCT03128710
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older · Male only
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Sep 27, 2026, 6:45 PM EDT
Withdrawn Not applicable Interventional

Proton Therapy for High Risk Prostate Cancer

NCT01811810
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation therapy (XRT), Androgen Deprivation Therapy (ADT), Chemotherapy
Radiation · Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 75 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Sep 27, 2026, 6:45 PM EDT
Completed Phase 4 Interventional

Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer

NCT00953277
View directory record Official record
Conditions
Peripheral Nerve Injury, Prostate Cancer, Radical Prostatectomy, Nerve Reconstruction, Cavernous Nerve Injury
Interventions
Processed Human Nerve Tissue Scaffold
Other
Lead sponsor
Axogen Corporation
Industry
Eligibility
18 Years to 70 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 11, 2024 · Synced Sep 27, 2026, 6:45 PM EDT
Completed Phase 1 Interventional

Docetaxel and Lycopene in Metastatic Prostate Cancer

NCT01949519
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
Lycopene and Docetaxel
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 10, 2018 · Synced Sep 27, 2026, 6:45 PM EDT
Completed Phase 1 Interventional Results available

Safety and Tolerability Study of MDV3100 in Combination With Docetaxel in Men With Advanced Prostate Cancer

NCT01565928
View directory record Official record
Conditions
Prostate Cancer
Interventions
MDV3100
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
3
States / cities
New York, New York • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 21, 2019 · Synced Sep 27, 2026, 6:45 PM EDT